An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours

Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: European Journal of Cancer - Volume 103, November 2018, Pages 17-23

H.-T. Arkenau, A. Italiano, G. Mak, M. Toulmonde, R.D. Baird, J. Garcia-Corbacho, R. Plummer, M. Flynn, M. Forster, R.H. Wilson, D. Tosi, A. Adenis, K. Donaldson, J. Posner, I. Kawabata, A. Arimura, S. Deva, J. Spicer,